Modalis Therapeutics Corporation (TYO:4883)
Japan
· Delayed Price · Currency is JPY 66.00
+12.00 (22.22%)
Apr 28, 2026, 3:30 PM JST
Modalis Therapeutics Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Cash & Equivalents | 2,812 | 3,575 | 1,883 | 2,933 | 4,936 | Upgrade
|
| Cash & Short-Term Investments | 2,812 | 3,575 | 1,883 | 2,933 | 4,936 | Upgrade
|
| Cash Growth | -21.34% | 89.86% | -35.80% | -40.58% | -8.95% | Upgrade
|
| Inventory | - | - | 6 | 40 | - | Upgrade
|
| Other Current Assets | 80 | 42 | 67 | 88 | 131 | Upgrade
|
| Total Current Assets | 2,892 | 3,617 | 1,956 | 3,061 | 5,067 | Upgrade
|
| Property, Plant & Equipment | - | - | - | - | 223 | Upgrade
|
| Long-Term Investments | 71 | 74 | 69 | 68 | 73 | Upgrade
|
| Other Intangible Assets | - | - | - | - | 705 | Upgrade
|
| Other Long-Term Assets | 1 | - | - | - | 1 | Upgrade
|
| Total Assets | 2,964 | 3,691 | 2,025 | 3,129 | 6,069 | Upgrade
|
| Accounts Payable | 1 | 1 | - | - | 1 | Upgrade
|
| Accrued Expenses | 25 | 20 | 91 | 17 | 25 | Upgrade
|
| Current Income Taxes Payable | 107 | 95 | 105 | 123 | 126 | Upgrade
|
| Other Current Liabilities | 1 | 1 | 2 | 1 | 28 | Upgrade
|
| Total Current Liabilities | 134 | 117 | 198 | 141 | 180 | Upgrade
|
| Long-Term Debt | - | - | 412 | - | - | Upgrade
|
| Long-Term Deferred Tax Liabilities | - | - | - | - | 5 | Upgrade
|
| Other Long-Term Liabilities | 38 | 28 | 36 | 49 | 335 | Upgrade
|
| Total Liabilities | 172 | 145 | 646 | 190 | 520 | Upgrade
|
| Common Stock | 1,728 | 1,758 | 1,217 | 2,094 | 2,744 | Upgrade
|
| Additional Paid-In Capital | 3,049 | 3,080 | 2,539 | 3,416 | 4,066 | Upgrade
|
| Retained Earnings | -2,037 | -1,325 | -2,410 | -2,605 | -1,266 | Upgrade
|
| Comprehensive Income & Other | 52 | 33 | 33 | 34 | 5 | Upgrade
|
| Shareholders' Equity | 2,792 | 3,546 | 1,379 | 2,939 | 5,549 | Upgrade
|
| Total Liabilities & Equity | 2,964 | 3,691 | 2,025 | 3,129 | 6,069 | Upgrade
|
| Total Debt | - | - | 412 | - | - | Upgrade
|
| Net Cash (Debt) | 2,812 | 3,575 | 1,471 | 2,933 | 4,936 | Upgrade
|
| Net Cash Growth | -21.34% | 143.03% | -49.85% | -40.58% | -8.95% | Upgrade
|
| Net Cash Per Share | 36.39 | 77.50 | 47.50 | 100.77 | 171.67 | Upgrade
|
| Filing Date Shares Outstanding | 89.55 | 73.55 | 33.81 | 30.09 | 29.04 | Upgrade
|
| Total Common Shares Outstanding | 86.67 | 69.4 | 33.36 | 29.36 | 28.97 | Upgrade
|
| Working Capital | 2,758 | 3,500 | 1,758 | 2,920 | 4,887 | Upgrade
|
| Book Value Per Share | 32.21 | 51.09 | 41.34 | 100.09 | 191.56 | Upgrade
|
| Tangible Book Value | 2,792 | 3,546 | 1,379 | 2,939 | 4,844 | Upgrade
|
| Tangible Book Value Per Share | 32.21 | 51.09 | 41.34 | 100.09 | 167.22 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.